Tag: dvt

Study finds significant association between low bilirubin levels and venous thromboembolism

A recent paper published by Hakan Duman (Recep Tayyip Erdoğan University, Rize, Turkey) and colleagues in the Journal of Vascular Surgery: Venous and Lymphatic...
vetex

New DVT device completes first-in-human trial

The first-in-human case using the new deep vein thrombosis (DVT) device Vetex thrombectomy catheter (Vetex Medical) has recently been completed in a multicentre study....

New developments in treatment of deep vein thrombosis

 An analysis of ATTRACT has recently been published in the journal Circulation, in which the authors examine the effect of pharmacomechanical catheter-directed therapy (PCDT) in ATTRACT patients...
PTS

New ATTRACT data show catheter-based therapy significantly reduces leg symptoms and...

A new study, recently published online in the journal Circulation, reports on outcomes from a subgroup of 391 patients with acute iliofemoral deep venous...

BTG to begin European distribution of EKOS Control unit 4.0

BTG has announced that the first EKOS Control Unit 4.0 have been shipped from BTG’s facility in Bothell (Washington, USA) to Europe, where full...

AngioJet thrombectomy can reduce dose and duration of lysis compared to...

Anna Louise Pouncey revealed at the European Venous Forum annual meeting (EVF; 28–30 June, Athens, Greece) the findings of the GSTT venous team (Guy’s...

Early identification of patients at high risk for iliofemoral DVT needs...

According to Fedor Lurie (Jobst Vascular Institute, Toledo, USA), who presented at the European Venous Forum Annual Meeting (EVF; 28–30 June, Athens, Greece), patients...

NexGen Medical Systems launches XCOIL large vessel thrombectomy system

NexGen Medical Systems, Inc., a US medical device company, has announced the successful completion of the first human use of their XCOIL large vessel (18mm)...

Setting the record straight: Clarifying the misconceptions of the ATTRACT trial

A special session during the pre-conference Day of Innovation and Science at the American Venous Forum annual meeting (AVF; 20–23 February, Tucson, USA) presented...

Cancer-associated VTE trial sees “lower rate of recurrent VTE with edoxaban...

Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in...
James Froehlich

Superficial venous thrombosis: Ultrasound, analysis of clot location, and risk factor...

At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of...

First European advice on deep vein thrombosis published in European Heart...

The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European...

Thrombosis: Both a physical and psychological event

There are two things you need to know about me. Firstly, I am a health psychologist, with a specialist interest in behaviour change, implementation, and impact....
Venous News

GARFIELD-VTE Registry sheds light on global heterogeneity of venous thromboembolism patients,...

The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress...

FDA grants priority review of Xarelto for a 10mg dose to...

The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...

ACCESS PTS study demonstrates efficacy of EKOS therapy for post-thrombotic syndrome

The results of the ACCESS PTS trial have been presented at the Society for Vascular Medicine 28th Annual Scientific Sessions (14–17 June, New Orleans,...

ATTRACT results are “a springboard” for future pharmacomechanical thrombolysis research

Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...

ATTRACT fails to meet primary endpoint, but experts agree results are...

Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...

Advances and challenges in the treatment of deep vein thrombosis

The goal of management of venous thromboembolic disease is to prevent thrombus extension or embolisation and to prevent early and late episodes of recurrence....

Two new real-world studies confirm positive efficacy and safety profile of...

Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...